kabutan

SEIKAGAKU CORPORATION(4548) Summary

4548
TSE Prime
SEIKAGAKU CORPORATION
680
JPY
-7
(-1.02%)
Dec 5, 2:14 pm JST
4.39
USD
Dec 5, 12:14 am EST
Result
PTS
outside of trading hours
679.1
Dec 5, 2:16 pm JST
Summary Chart Historical News Financial Result
PER
27.5
PBR
0.51
Yield
4.41%
Margin Trading Ratio
16.63
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
686 JPY 4.42 USD
Previous Close Dec 4
687 JPY 4.42 USD
High Dec 5, 9:02 am
687 JPY 4.42 USD
Low Dec 5, 12:32 pm
679 JPY 4.37 USD
Volume
95,700
Trading Value
0.07B JPY 0.42M USD
VWAP
682.12 JPY 4.41 USD
Minimum Trading Value
68,000 JPY 439 USD
Market Cap
0.04T JPY 0.25B USD
Number of Trades
165
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
266
1-Year High Dec 2, 2025
1,012
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 99,500 1,634,000 16.42
Nov 21, 2025 85,100 1,600,400 18.81
Nov 14, 2025 108,800 1,609,900 14.80
Nov 7, 2025 130,000 1,609,700 12.38
Oct 31, 2025 132,900 1,565,000 11.78
Company Profile
SEIKAGAKU CORPORATION specializes in the development of products related to joint diseases. Its hyaluronic acid preparations are distributed through partnerships with Kaken Pharmaceutical and Santen Pharmaceutical.
Sector
Pharmaceuticals
SEIKAGAKU CORPORATION engages in the research, development, manufacturing, procurement, and sales of pharmaceuticals and LAL (Limulus Amebocyte Lysate) products, including endotoxin detection reagents. In its pharmaceutical business, the company focuses on joint function improving agents as its main product line, while also offering ophthalmic surgical aids and treatments for lumbar disc herniation. Additionally, the company manufactures pharmaceutical ingredients and provides contract manufacturing services for pharmaceuticals. In the LAL business, SEIKAGAKU CORPORATION offers endotoxin detection reagents and glucan measurement in vitro diagnostic products. The company has several subsidiaries both domestically and internationally, conducting pharmaceutical and medical device development in North America, as well as manufacturing and sales operations overseas.